Vyome Holdings (HIND) Depreciation & Amortization (CF) (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Depreciation & Amortization (CF) of $2605.0 for Q1 2026, down 26.06% year-over-year from $3523.0 in Q1 2025, and down 12.23% quarter-over-quarter from $2968.0 in Q4 2025.
Vyome Holdings (HIND) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Vyome Holdings' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $2605.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 26.06% year-over-year to $2605.0; the TTM figure through Mar 2026 stood at $12379.0 (down 30.51% YoY), while the FY2025 annual figure was $11985.0, down 30.91% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $2605.0, down from $2968.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $94000.0 in Q1 2022, with the low at $2605.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $6000.0 (2024), against an average of $28658.4.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) jumped 172.73% in 2022, then tumbled 88.65% in 2024.
- Vyome Holdings' Depreciation & Amortization (CF) stood at $59000.0 in 2022, then plunged by 88.14% to $7000.0 in 2023, then sank by 44.8% to $3864.0 in 2024, then decreased by 23.19% to $2968.0 in 2025, then decreased by 12.23% to $2605.0 in 2026.
- Business Quant data shows HIND's Depreciation & Amortization (CF) at $2605.0 in Q1 2026, $2968.0 in Q4 2025, and $2806.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | 2,610.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,610.00 |
| Jun 30, 2026 | 2,610.00 |
| Mar 31, 2026 | 2,605.00 |
| Mar 31, 2026 | 2,605.00 |
| Dec 31, 2025 | 2,968.00 |
| Dec 31, 2025 | 2,968.00 |
| Sep 30, 2025 | 2,806.00 |
| Sep 30, 2025 | 2,806.00 |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 3,523.00 |
| Mar 31, 2025 | 3,523.00 |
| Dec 31, 2024 | 3,864.00 |
| Dec 31, 2024 | 3,864.00 |
| Sep 30, 2024 | 4,427.00 |
| Sep 30, 2024 | 4,427.00 |
| Jun 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |